On Feb. 17, 2012, the FDA announced Korlym (mifepristone) was approved to control high blood sugar levels (hyperglycemia) in adults with endogenous Cushing’s syndrome.

This drug was approved for use in patients with endogenous Cushing’s syndrome who are not candidates for surgery. Korlym is manufactured by Corcept Therapeutics of Menlo Park, Calif.